Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules

Author(s):  Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa

Issue:  Sep/Oct 2015 - Volume 19, Number 5
View All Articles in Issue

Page(s):  414-419

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 1
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 2
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 3
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 4
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 5
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 6

Download in electronic PDF format for $75

Abstract:  The purpose of this research was to collect, analyze, and compare stability data for levothyroxine (T4) powder in the anhydrous and pentahydrate form when prepared as an aliquot and in capsules. Two different compounding pharmacies, Central Iowa Compounding and Gateway Medical Pharmacy, used different forms of T4 and aliquot formulations, which were studied to determine the beyond-use date at ±5% or ±10% of labeled strength. T4 was extracted from aliquot and capsule formulations and assessed using reverse-phase highperformance liquid chromatography validated to differentiate between the degraded and original forms of T4. The results indicate that T4 1:100 aliquot formulation prepared with silica gel or Avicel as filler are stable for 120 days at ±10% labeled potency, but at ±5% labeled potency, the silica gel and Avicel aliquot formulations are stable for 45 and 30 days, respectively. The silica gel capsules prepared from fresh aliquot were stable for 120 days at ±10% labeled potency and 90 days at ±5% labeled potency, while the Avicel capsules prepared from fresh aliquot were stable for 180 days at both ±10% and ±5% labeled potency. Avicel capsules prepared from old aliquot (120 days) and fresh aliquot (1 day) were also compared for stability. The old aliquot Avicel capsules were stable for 14 days at ±5% labeled potency and 150 days at ±10% labeled potency, while new aliquot Avicel capsules were stable for 180 days at both ±10% and ±5% labeled potency. Based on our data, there can be significant variation in the beyond-use dates assigned to T4 capsules based on the diluents used for aliquots, the final capsule formulations, and the potency standards applied. These results also indicate that pharmacists must exercise caution when using older aliquots and may have to assign shorter beyond-use dates.

Related Keywords: Jeff Fortner, PharmD, Jason Salton, PharmD, Christie Carlson, RPh, Rich Wheeler, RPh, Brianna Cote, Deepa Rao, PhD, levothyroxine, hypothyroidism, thyroid T4 replacement hormone, anhydrous, pentahydrate, aliquots, capsules, stability, potency standards, storage temperature

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff
, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Sep/Oct 2015
Pg. 414-419

Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol
Snyder Scott
, Listecki Robert E
Sep/Oct 2012
Pg. 376-380

Levothyroxine Sodium 100-mcg Capsules
Allen Loyd V Jr
Nov/Dec 2013
Pg. 505

Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement
Milner Martin
Jul/Aug 2005
Pg. 268-273

Levothyroxine Sodium 40-micro-g/mL Oral Liquid
Allen Loyd V Jr
May/Jun 2007
Pg. 247

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna
, Ross Bethany, Fortner Jeff, Rao Deepa
May/Jun 2018
Pg. 252-256

Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures
Nahata Milap C
Sep/Oct 2015
Pg. 428-431

Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
Nov/Dec 2008
Pg. 488-497

Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates)
Brandin Thibaut
, Wasilewski Maya, Panuccio Camille, Bouguergour Cyrielle, Primas Nicolas, Lamy Edouard, Jean Christophe, Bertault-Peres Pierre, Rathelot Pascal, Curti Christophe, Vanelle Patrice
Mar/Apr 2022
Pg. 150-154

Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
Jan/Feb 2024
Pg. 34-43

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh
, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Jan/Feb 2021
Pg. 73-81

Stability of Levothyroxine Sodium Injection in Polypropylene Syringes
Gupta Vishnu D
Nov/Dec 2000
Pg. 482-483

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Thyroid Potency Calculations
Stack Bob
Jul/Aug 2010
Pg. 306-309

Basics of Compounding with Dilutions and Concentrates
Allen Loyd V Jr
Jan/Feb 2017
Pg. 39-45

Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal
, Levesque Dan, Frye John, Rashid Mamoon
Jul/Aug 2020
Pg. 322-326

Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid
, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Sep/Oct 2017
Pg. 418-425

Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets
Alexander Kenneth S
, Kothapalli Madhu R, Dollimor David
Jan/Feb 1997
Pg. 60-63

Return to Top